Literature DB >> 17606951

The economic burden of chronic cardiovascular disease for major insurers.

Justin G Trogdon1, Eric A Finkelstein, Isaac A Nwaise, Florence K Tangka, Diane Orenstein.   

Abstract

Accounting models provide less precise estimates of disease burden than do econometric models. The authors seek to improve these estimates for cardiovascular disease using a nationally representative survey and econometric modeling to isolate the proportion of medical expenditures attributable to four chronic cardiovascular diseases: stroke, hypertension, congestive heart failure, and other heart diseases. Approximately 17% of all medical expenditures, or $149 billion annually, and nearly 30% of Medicare expenditures are attributable to these diseases. Of the four diseases, hypertension accounts for the largest share of prescription expenditures across payers and the largest share of all Medicaid expenditures. The large number of people with cardiovascular disease who are eligible for both Medicare and Medicaid could lead to large shifts in the burden to these payers as prescription drug coverage is included in Medicare. A societal perspective is important when describing the economic burden of cardiovascular disease.

Entities:  

Mesh:

Year:  2007        PMID: 17606951     DOI: 10.1177/1524839907303794

Source DB:  PubMed          Journal:  Health Promot Pract        ISSN: 1524-8399


  39 in total

1.  Patient-physicians' information exchange in outpatient cardiac care: time for a heart to heart?

Authors:  Urmimala Sarkar; Dean Schillinger; Kirsten Bibbins-Domingo; Anna Nápoles; Leah Karliner; Eliseo J Pérez-Stable
Journal:  Patient Educ Couns       Date:  2010-10-28

2.  The economic burden of exposure to secondhand smoke for child and adult never smokers residing in U.S. public housing.

Authors:  Jacquelyn Mason; William Wheeler; Mary Jean Brown
Journal:  Public Health Rep       Date:  2015 May-Jun       Impact factor: 2.792

3.  Neighborhood SES is particularly important to the cardiovascular health of low SES individuals.

Authors:  Jennifer Morozink Boylan; Stephanie A Robert
Journal:  Soc Sci Med       Date:  2017-07-08       Impact factor: 4.634

4.  Longitudinal trajectories of hospital performance across targeted cardiovascular conditions in the USA.

Authors:  Muthiah Vaduganathan; Cian P McCarthy; Colby Ayers; Deepak L Bhatt; Dharam J Kumbhani; James A de Lemos; Gregg C Fonarow; Ambarish Pandey
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2020-01-01

Review 5.  Atherosclerotic cardiovascular disease: a review of initiators and protective factors.

Authors:  Mohammed S Ellulu; Ismail Patimah; Huzwah Khaza'ai; Asmah Rahmat; Yehia Abed; Faisal Ali
Journal:  Inflammopharmacology       Date:  2016-01-11       Impact factor: 4.473

6.  Employer-based health initiative: impact on employees' cardiovascular outcomes.

Authors:  Claiborne E Reeder; Christine H Divers; Del Deem; Becky J Cherney; Gaye Fortner; Louise Y Probst
Journal:  Am Health Drug Benefits       Date:  2009-02

7.  Hypertension-associated hospitalizations and costs in the United States, 1979-2006.

Authors:  Guijing Wang; Jing Fang; Carma Ayala
Journal:  Blood Press       Date:  2013-07-25       Impact factor: 2.835

8.  Estimating the potential health impact and costs of implementing a local policy for food procurement to reduce the consumption of sodium in the county of Los Angeles.

Authors:  Lauren N Gase; Tony Kuo; Diane Dunet; Steven M Schmidt; Paul A Simon; Jonathan E Fielding
Journal:  Am J Public Health       Date:  2011-06-16       Impact factor: 9.308

9.  Impact of hypertension on healthcare costs among children.

Authors:  Todd P Gilmer; Patrick J O'Connor; Alan R Sinaiko; Elyse O Kharbanda; David J Magid; Nancy E Sherwood; Kenneth F Adams; Emily D Parker; Karen L Margolis
Journal:  Am J Manag Care       Date:  2014-08       Impact factor: 2.229

Review 10.  Plaque assessment by coronary CT.

Authors:  Bálint Szilveszter; Csilla Celeng; Pál Maurovich-Horvat
Journal:  Int J Cardiovasc Imaging       Date:  2015-08-18       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.